SITC News

Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC ...

Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC manuscript ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | JITC at AACR 2025 40 th Anniversary Series | Popular Archive Articles Letter from the Editor Hello JITC Readers, I just returned from London with other Editors-in-Chief for the 76 journals (like ours) published by the BMJ Group. We focused on many issues that confront our knowledge workers in the modern era, including the use of multimedia, ethics, how to improve the quality of content and… the state of our world. I was asked by many ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | JITC at AACR 2025 40 th Anniversary Series | Popular Archive Articles Letter from the Editor Hello JITC Readers, I just returned from London with other Editors-in-Chief for the 76 journals (like ours) published by the BMJ Group. We focused on many issues that confront our knowledge workers in the modern era, including the use of multimedia, ethics, how to improve the quality of content and… the state of our world. I was asked by many ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...

This webinar on April 2 explored what b iomarker discovery for cancer immunotherapy entails using high-dimensional multi- omic assays that can be difficult to interpret, particularly in the setting of challenging clinical trial designs such as small cohort size or unbalanced response rates. This webinar therefore addressed advances in computational science and biostatistics that allow for rigorous interpretation of complex exploratory biomarker data, when most studies are typically only powered for clinical endpoints. View the webinar for FREE on-demand HERE.

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...

The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive manuscript, “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols” in the Journal for ImmunoTherapy of Cancer (JITC) . This work provides an in-depth examination of evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity that are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing ...

Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) would like to thank Peter Marks, MD, PhD, Marc Theoret, MD, and Paul Kluetz, MD, of the U.S. Food and Drug Administration (FDA) for their significant contributions across the field of oncology and their positive impact on public health. The development of cancer immunotherapy as we know it today - serving as first-line treatment for numerous cancer types - represents one such advance in oncology that would not have been possible without the tireless work ethic, collaboration, and determination of these individuals to improve ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances ...

Artificial intelligence- and machine learning-based approaches to identify biomarkers of patient response ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

A Message from the President For 40 years, the Society for Immunotherapy of Cancer (SITC) has ...

A Message from the President During this period of significant change within the U.S. federal ...

A Message from the President Over the last 12 months, you collectively dedicated your creativity, ...